Comparative Pharmacology
Head-to-head clinical analysis: ADLYXIN versus SAXENDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADLYXIN versus SAXENDA.
ADLYXIN vs SAXENDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that increases insulin secretion, decreases glucagon secretion, delays gastric emptying, and promotes satiety via central GLP-1 receptor activation.
Subcutaneous injection: 10 mcg once daily within 60 minutes before the first meal of the day; may increase to 20 mcg once daily after 2 weeks.
Subcutaneous injection once daily, starting at 0.6 mg and titrating weekly by 0.6 mg increments to a maintenance dose of 3.0 mg.
None Documented
None Documented
Terminal elimination half-life is 2–3 hours after subcutaneous administration, supporting a twice-daily dosing regimen.
11–13 hours (subcutaneous). Steady-state is reached after 3–5 once-daily doses.
Renal (predominantly via glomerular filtration and proteolytic degradation; approximately 35% of the dose is excreted unchanged in urine, with the remainder as metabolites and small peptides).
Renal excretion of intact liraglutide is minimal; approximately 6% is excreted as intact liraglutide in urine. The remainder is metabolized and eliminated via the kidneys and feces, with no single metabolite accounting for >10% of the dose.
Category C
Category C
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist, Anti-obesity